Combination therapy with beta-adrenergic receptor antagonists and phosphodiesterase inhibitors for chronic heart failure.
about
Robustness portraits of diverse biological networks conserved despite order-of-magnitude parameter uncertainty.Modeling cardiac β-adrenergic signaling with normalized-Hill differential equations: comparison with a biochemical model.Differential regulation of two palmitoylation sites in the cytoplasmic tail of the beta1-adrenergic receptorPDE3, but not PDE4, reduces β₁ - and β₂-adrenoceptor-mediated inotropic and lusitropic effects in failing ventricle from metoprolol-treated patients.
P2860
Combination therapy with beta-adrenergic receptor antagonists and phosphodiesterase inhibitors for chronic heart failure.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Combination therapy with beta- ...... ors for chronic heart failure.
@en
Combination therapy with beta- ...... ors for chronic heart failure.
@nl
type
label
Combination therapy with beta- ...... ors for chronic heart failure.
@en
Combination therapy with beta- ...... ors for chronic heart failure.
@nl
prefLabel
Combination therapy with beta- ...... ors for chronic heart failure.
@en
Combination therapy with beta- ...... ors for chronic heart failure.
@nl
P2093
P2860
P356
P1433
P1476
Combination therapy with beta- ...... ors for chronic heart failure.
@en
P2093
Benjamin W Van Tassell
Mark A Munger
Matthew Movsesian
Przemyslaw Radwanski
P2860
P304
P356
10.1592/PHCO.28.12.1523
P407
P577
2008-12-01T00:00:00Z